Today, drug development is carried out in human subjects and animals. However, as computing power and the number of sophisticated technology platforms grow exponentially, and our knowledge of human health and disease increases, the virtualization of clinical research and development will grow steadily.
To improve performance of computationally intensive algorithms, Phoenix NLME jobs utilize parallel computing to take full advantage of computing resources. In this webinar, we illustrated how parallel computing reduces analysis time and demonstrated how easy it is to submit jobs to Torque/SGE grids running on physical Linux and Amazon EC2 cloud.
PRINCETON, NJ – July 21, 2016 – Certara today announced the appointment of Nathan Teuscher, PhD, to vice president of pharmacometric solutions. In his new role, Dr. Teuscher will lead the company’s Phoenix software division. He previously served as Certara’s vice president of scientific training.
Learn how modeling and simulation approaches support the goal of precision dosing—providing the right drug dose to maximize therapeutic benefit, while reducing risk for each individual patient.
PRINCETON, NJ – July 20, 2016 – Mitsubishi Tanabe, the 34th leading biopharmaceutical company and the tenth leading Japanese pharmaceutical company, has joined Certara’s Simcyp Consortium and licensed its proprietary Simcyp Population-based Simulator.
The topic of this webinar is to introduce mathematical tools to model PK/PD systems with distributed delays.
MBMA integrates internal and external drug development data to inform proprietary commercial and R&D decisions. The insights gained via MBMA support designing less costly and more precise trials with an eye toward achieving commercial success for both the drug and portfolio.
